|
|
 |
|
Viewing report
|
|
|
|
TNM Classification of Malignant Tumours, 7th Edition
John Wiley and Sons Ltd, Nov 2009, Pages: 256
TNM Classification of Malignant Tumours, 7th Edition offers a truly international approach to cancer classification and staging, with the latest information and best evidence carefully vetted and included by a multidisciplinary panel of experts from around the world. The material is therefore immediately applicable to patients worldwide, and not influenced by any particular healthcare system.
The book's greatest virtue continues to be its simplicity, distilling and arranging complex data in a way that is immediately applicable wherever cancer patients are seen.
TNM Classification of Malignant Tumours, 7th Edition provides the latest, internationally agreed-upon standards to describe and categorize cancer stages and progression. Published in affiliation with the International Union Against Cancer (UICC), this authoritative guide contains important updated organ-specific classifications that oncologists and other professionals who manage patients with cancer need to accurately classify tumours for staging, prognosis and treatment.
The major alterations addressed in the 7th Edition concern carcinomas of the oesophagus and the gastroesophageal junction, stomach, lung, appendix, biliary tract, skin, and prostate. In addition, there are several entirely new classifications:
- gastrointestinal carcinoids (neuroendocrine tumours)
- gastrointestinal stromal tumour
- upper aerodigestive mucosal melanoma
- Merkel cell carcinoma
- uterine sarcomas
- intrahepatic cholangiocarcinoma
- adrenal cortical carcinoma.
A new approach has also been adopted to separate anatomical stage groupings from prognostic groupings in which other prognostic factors are added to T, N, and M categories. These new prognostic groupings, as well as the traditional anatomical groupings, are presented for oesophageal and prostate carcinomas.
Customers who bought this item also bought
Drug Delivery in Cancer - Technologies, Markets and Companies
Cancer and its Management, 6th Edition
Dealmaking and Industry Outlook: Targeted Cancer Therapies
Personalized Medicine - Scientific and Commercial Aspects
Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
Optimizing Treatment for Bone Metastases in Advanced Cancers 2011
Hematology and Medical Oncology Best Practices
Advancing Molecular Diagnostics to Personalize Cancer Therapy
Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success
Oncology Therapeutics Market to 2017 - High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development
|
|
|
|
